Abhinav Khanna, MD

Articles by Abhinav Khanna, MD

Surgical Perspectives on Perioperative Therapy in MIBC

ByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MD

June 17th 2026

Watch surgeons review cystectomy after immunotherapy—tissue planes stay familiar, lymph node dissection matters, and adjuvant choices remain unclear.

Surgical Timing in the Perioperative Era of MIBC

ByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MD

June 17th 2026

EV-pembro and immunotherapy may shorten time to cystectomy, with fewer chemo-era blood issues but new immune toxicities to manage.

Emerging Combination Perioperative Strategies in MIBC

ByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MD

June 10th 2026

New bladder cancer trials test perioperative immunotherapy combos, weighing added enfortumab vedotin vs adjuvant de-escalation to boost durable cures.

Addressing Unmet Needs in MIBC

ByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MD

June 10th 2026

EV/pembrolizumab in EV-304 delivers strong pathologic response, event-free and overall survival gains versus standard chemo, reshaping neoadjuvant bladder cancer choices.

Comparing Perioperative Strategies in Cisplatin-Eligible MIBC

ByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MD

June 3rd 2026

This episode, titled “Comparing Perioperative Strategies in Cisplatin-Eligible MIBC,” features panelists discussing how the KEYNOTE-B15/EV-304 trial is reshaping perioperative treatment considerations for patients with muscle-invasive bladder cancer (MIBC). The expert faculty review the study design evaluating perioperative enfortumab vedotin plus pembrolizumab (EVP) compared with standard neoadjuvant gemcitabine-cisplatin (Gem-CIS), and discuss how these findings may influence treatment selection in cisplatin-eligible patients.

Perioperative Therapy Expansion in Cisplatin-Ineligible MIBC

ByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MD

June 3rd 2026

In “Perioperative Therapy Expansion in Cisplatin-Ineligible MIBC,” our panel explores how the treatment paradigm for muscle-invasive bladder cancer (MIBC) is rapidly evolving with the emergence of effective perioperative therapies for cisplatin-ineligible patients. The expert faculty discuss how traditional approaches that relied heavily on determining cisplatin eligibility are changing in light of recent clinical trial data supporting enfortumab vedotin plus pembrolizumab (EVP) in patients who historically would have proceeded directly to surgery.

The Emerging Perioperative Era in MIBC with the NIAGARA Trial

ByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MD

May 27th 2026

In this episode, “The Emerging Perioperative Era in MIBC with the NIAGARA Trial,” the expert faculty explore how the NIAGARA trial is reshaping the treatment landscape for muscle-invasive bladder cancer (MIBC). The panel reviews the clinical data supporting perioperative durvalumab plus gemcitabine-cisplatin (GC) in cisplatin-eligible patients, including findings related to pathologic complete response, event-free survival, overall survival, and safety, and discusses how these outcomes are influencing treatment strategies in clinical practice.

The Evolving Treatment Landscape in MIBC

ByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MD

May 27th 2026

Welcome back to another Urology Times Peer Exchange series. In this episode titled, “The Evolving Treatment Landscape in MIBC,” the expert faculty discuss how the treatment landscape for muscle-invasive bladder cancer (MIBC) is evolving with the emergence of perioperative treatment strategies that integrate systemic therapy before and after surgery.